[Cardiological use of glucagon-zinc-protamine in diabetes].
D000208:Acute Disease; D000319:Adrenergic beta-Antagonists / Q000009:adverse effects; D000368:Aged; D002986:Clinical Trials as Topic; D003692:Delayed-Action Preparations; D048909:Diabetes Complications; D005260:Female; D005934:Glucagon / Q000627:therapeutic use*; D006331:Heart Diseases / Q000139:chemically induced / Q000188:drug therapy*; D006333:Heart Failure / Q000188:drug therapy; D006801:Humans; D008297:Male; D008875:Middle Aged; D009203:Myocardial Infarction / Q000188:drug therapy; D011479:Protamines / Q000627:therapeutic use*; D012770:Shock, Cardiogenic / Q000188:drug therapy; D015032:Zinc / Q000627:therapeutic use*
D000319:Adrenergic beta-Antagonists; D003692:Delayed-Action Preparations; D011479:Protamines; D005934:Glucagon; D015032:Zinc
Uso cardiologico del glucagone-protamina-zinco in corso di diabete.